Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2012 A Phase II Trial of Erlotinib plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy. MDACC Principal Investigator:
2. 2012 A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) SEARCH Trial Principal Investigator
3. 2012 A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma Clinical Principal Investigator
4. 2012 A Phase III randomized, double-blind, placebo controlled study of Sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation. MDACC Co-Principal Investigator
5. 2012 A Phase I study of proton radiotherapy and Bevacizumab for primary liver tumors. MDACC Co-Principal Investigator
6. 2012 A Phase II Study of Yttrium-90 Microspheres (SIR-Spheres) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma MDACC Co-Principal Investigator
7. 2012 Laboratory Protocol for Collection of Residual Tissue and Sample Analyses from Patients with Cholangiocarcinoma (Gallbladder and Biliary Tract Cancer) MDACC Principal Investigator


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.